Minoxidil topical cream petition
This article was originally published in The Tan Sheet
Executive Summary
Law firm Baker & Hostetler asks FDA to allow an abbreviated new drug application to change the topical dosage form for private-label Rogaine, according to a petition filed Dec. 11. The petition notes that changing the dosage for the hair regrowth product from a topical solution to a cream provides better application control and reduces the risk of skin irritation to non-affected areas. It requests the dosage change for the generic versions of Rogaine (For Women) 2 percent and Rogaine Extra Strength (For Men) 5 percent. The foam delivery form of Rogaine is patented through 2019 (1"The Tan Sheet" Sept. 11, 2006, p. 5)
You may also be interested in...
Rogaine Foam Patents To Keep Product Covered Through 2019, Pfizer Says
Pfizer Consumer Healthcare's new foam delivery form ofRogaine (minoxidil) carries three years of marketing exclusivity and is patent-protected through 2019, the firm announced Sept. 5
Shortlist Revealed Ahead Of October Awards
Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.
Minute Insight: Vicarious’ Future Gets Precarious
The surgical robotics start-up may be de-listed from the New York Stock Exchange (NYSE) due to its low current share price. Some analysts believe the company can survive long enough to earn FDA de novo clearance for its robotic surgical system.